ATN-161

SKU: orb1710371

Description

ATN-161 is a peptide antagonist of integrin α5β1, inhibiting VEGF-driven migration and angiogenesis in hCECs. It also blocks spike protein binding to α5β1, suggesting research applications in anti-angiogenesis studies and as a potential therapeutic agent against SARS-CoV-2 infection in vitro.

Research Area

Signal Transduction

Key Properties

• CAS Number: 262438-43-7
• MW: 597.64
• Formula: C₂₃H₃₅N₉O₈S
• SMILES: C(N[C@@H](CC1=CN=CN1)C(N[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(N)=O)=O)CS)=O)CO)=O)(=O)[C@H]2N(C(C)=O)CCC2
• Target: Integrin
• Solubility: DMSO:20 mg/mL (33.46 mM);H2O:≥ 8 mg/mL

Bioactivity

• In Vivo:
  In the α5β1-negative human colon cancer xenograft model (HT29), ATN-161 treatment significantly reduced tumor weight and vascular density . Intravitreal injection of ATN-161 after laser photocoagulation effectively suppressed leakage and neovascularization of choroidal neovascularization (CNV), with efficacy comparable to that of AF564 .
• In Vitro:
  Compared to the control group and monotherapy, ATN-161 combined with 5-FU significantly inhibited tumor cell proliferation and markedly increased the number of apoptotic (TUNEL-positive) tumor cells. In comparison to the control group, ATN-161 reduced endothelial cell (EC) counts by 21% after 48 hours of incubation . ATN-161 was able to inhibit VEGF-induced migration of Homo sapiens corneal endothelial cells (hCECs) and the formation of capillary-like tubular structures, but showed no inhibitory effect on cell proliferation. Starting from a concentration of 100 nM, ATN-161 reduced VEGF-induced cell migration in a dose-dependent manner.

Storage & Handling

• Storage: store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Integrin α5β1, ATN 161, ATN161, ATN-161

Compound Identifiers

PubChem CID

9960285